Symbols / CVAC
CVAC Chart
About
As of December 18, 2025, CureVac N.V. was acquired by BioNTech SE. CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In addition, the company offers The RNA Printer, a downsized, integrated, and highly automated process for manufacturing of mRNA vaccines and therapeutics. Further, it develops prophylactic vaccine lead candidate that addresses urinary tract infections targeting uropathogenic E. coli (UPEC) bacteria; vaccine candidates CV0601 and CV0701, which are in phase 2 clinical study against SARS-CoV-2; vaccines for off-the-shelf and fully personalized cancer precision immunotherapies in oncology; and CVGBM for treating cancer. Additionally, the company develops, manufactures, and commercializes mRNA vaccines targeting SARS-CoV-2 variants; antigen cancer precision immunotherapy candidate that targets squamous non-small cell lung cancer; and antigen cancer precision immunotherapy candidate CVGBM that is tested in patients with surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma. CureVac N.V. was incorporated in 2000 and is headquartered in Tübingen, Germany.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.05B |
| Enterprise Value | 462.19M | Income | 128.82M | Sales | 70.74M |
| Book/sh | 5.63 | Cash/sh | 2.30 | Dividend Yield | — |
| Payout | 0.00% | Employees | 825 | IPO | Aug 14, 2020 |
| P/E | 6.96 | Forward P/E | -8.02 | PEG | — |
| P/S | 14.83 | P/B | 0.83 | P/C | — |
| EV/EBITDA | 2.39 | EV/Sales | 6.53 | Quick Ratio | 1.88 |
| Current Ratio | 3.70 | Debt/Eq | 4.03 | LT Debt/Eq | — |
| EPS (ttm) | 0.67 | EPS next Y | -0.58 | EPS Growth | 24.00% |
| Revenue Growth | -89.00% | Earnings | 2026-04-09 | ROA | — |
| ROE | — | ROIC | — | Gross Margin | 93.29% |
| Oper. Margin | 5.73% | Profit Margin | 182.11% | Shs Outstand | 225.17M |
| Shs Float | 180.77M | Short Float | 0.49% | Short Ratio | 0.32 |
| Short Interest | — | 52W High | 5.72 | 52W Low | 2.48 |
| Beta | 1.84 | Avg Volume | 1.24M | Volume | 728.78K |
| Target Price | — | Recom | None | Prev Close | $4.66 |
| Price | $4.66 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$4.66
Latest analyst target
3. DCF / Fair value
$10.05
Fallback: EPS × 15 (assumed fair P/E). No FCF data; use with …
Ratings
Current target
$4.66
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-06-26 | down | UBS | Buy → Neutral | $6 |
| 2025-06-13 | down | Jefferies | Buy → Hold | $5 |
| 2025-05-28 | reit | JMP Securities | Market Outperform → Market Outperform | $10 |
| 2025-04-30 | main | UBS | Buy → Buy | $12 |
| 2025-02-14 | reit | JMP Securities | Market Outperform → Market Outperform | $16 |
| 2024-09-16 | reit | JMP Securities | Market Outperform → Market Outperform | $16 |
| 2024-08-16 | main | JMP Securities | Market Outperform → Market Outperform | $16 |
| 2024-07-03 | reit | JMP Securities | Market Outperform → Market Outperform | $18 |
| 2024-04-25 | down | Leerink Partners | Outperform → Market Perform | $4 |
| 2024-04-05 | reit | Guggenheim | — → Neutral | — |
| 2021-04-26 | init | Guggenheim | — → Buy | — |
| 2020-12-10 | down | Credit Suisse | Neutral → Underperform | — |
| 2020-09-08 | init | B of A Securities | — → Buy | $70 |
| 2020-09-08 | init | Jefferies | — → Hold | $58 |
| 2020-09-08 | init | Credit Suisse | — → Neutral | $68 |
- CureVac is now part of the BioNTech Group - CureVac hu, 18 Dec 2025 11
- CureVac: The Hidden Value Of The mRNA Wallet - Seeking Alpha Wed, 01 Oct 2025 07
- BioNTech’s CureVac Deal Put A Floor Under A Volatile Stock - Finimize ue, 13 Jan 2026 08
- Alpine Associates Management Inc. Grows Stock Holdings in CureVac N.V. $CVAC - MarketBeat hu, 12 Feb 2026 08
- CureVac (Nasdaq: CVAC) shareholders approve BioNTech exchange offer with 99.16% vote - Stock Titan ue, 25 Nov 2025 08
- CureVac Enters Oversold Territory (CVAC) - Nasdaq ue, 16 Dec 2025 08
- BioNTech to acquire CureVac in $1.25 billion all-stock deal By Investing.com - Investing.com Nigeria Sat, 06 Dec 2025 08
- CureVac Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis Mon, 22 Dec 2025 08
- CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech - Yahoo Finance Fri, 20 Jun 2025 07
- Can CVAC stock deliver consistent earnings growth - July 2025 Pullbacks & Technical Pattern Alert System - mfd.ru Fri, 20 Feb 2026 14
- Reassessing CureVac (NasdaqGM:CVAC) Valuation After Its Removal From the NASDAQ Biotechnology Index - simplywall.st hu, 04 Dec 2025 08
- CureVac N.V. (CVAC) Stock Analysis: Navigating a Biotech Pioneer with a Strong Return on Equity - DirectorsTalk Interviews Fri, 03 Oct 2025 07
- Stocks making the biggest moves midday: Chime Financial, Oracle, Boeing, CureVac, Datadog and more - CNBC hu, 12 Jun 2025 07
- CureVac Reports Q3 2025 Financials and BioNTech Transaction Progress - TipRanks Mon, 24 Nov 2025 08
- Top Stock Movers Now: Oracle, Boeing, CureVac, and More - Investopedia hu, 12 Jun 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 126.58K | -302.50K | 439.46 | 0.00 |
| TaxRateForCalcs | 0.15 | 0.25 | 0.00 | 0.00 |
| NormalizedEBITDA | 208.85M | -235.37M | -223.98M | -386.49M |
| TotalUnusualItems | 842.00K | -1.21M | 869.00K | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 842.00K | -1.21M | 869.00K | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | 162.19M | -260.17M | -249.03M | -411.72M |
| ReconciledDepreciation | 18.81M | 23.39M | 23.74M | 15.67M |
| ReconciledCostOfRevenue | 94.83M | 114.80M | 171.61M | 231.50M |
| EBITDA | 209.69M | -236.58M | -223.12M | -386.49M |
| EBIT | 190.88M | -259.97M | -246.86M | -402.16M |
| NetInterestIncome | 12.36M | 15.45M | -567.00K | -235.00K |
| InterestExpense | 0.00 | 0.00 | 2.30M | 10.34M |
| InterestIncome | 12.36M | 15.41M | 1.73M | 10.10M |
| NormalizedIncome | 161.47M | -259.26M | -249.90M | -411.72M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 162.19M | -260.17M | -249.03M | -411.72M |
| TotalExpenses | 357.50M | 327.96M | 316.88M | 515.25M |
| TotalOperatingIncomeAsReported | 177.68M | -274.21M | -249.46M | -412.26M |
| DilutedAverageShares | 225.27M | 220.91M | 189.07M | 186.01M |
| BasicAverageShares | 224.38M | 220.91M | 189.07M | 186.01M |
| DilutedEPS | 0.72 | -1.18 | -1.32 | -2.21 |
| BasicEPS | 0.72 | -1.18 | -1.32 | -2.21 |
| DilutedNIAvailtoComStockholders | 162.19M | -260.17M | -249.03M | -411.72M |
| NetIncomeCommonStockholders | 162.19M | -260.17M | -249.03M | -411.72M |
| NetIncome | 162.19M | -260.17M | -249.03M | -411.72M |
| NetIncomeIncludingNoncontrollingInterests | 162.19M | -260.17M | -249.03M | -411.72M |
| NetIncomeContinuousOperations | 162.19M | -260.17M | -249.03M | -411.72M |
| TaxProvision | 28.70M | 198.00K | -126.00K | -782.00K |
| PretaxIncome | 190.88M | -259.97M | -249.16M | -412.50M |
| OtherIncomeExpense | 842.00K | -1.21M | 869.00K | |
| SpecialIncomeCharges | 2.06M | 1.40M | 0.00 | |
| GainOnSaleOfPPE | 1.20M | 785.00K | 0.00 | |
| OtherSpecialCharges | -860.00K | -610.00K | ||
| GainOnSaleOfSecurity | 842.00K | -1.21M | 869.00K | |
| NetNonOperatingInterestIncomeExpense | 12.36M | 15.45M | -567.00K | -235.00K |
| TotalOtherFinanceCost | -37.00K | 1.00K | ||
| InterestExpenseNonOperating | 0.00 | 0.00 | 2.30M | 10.34M |
| InterestIncomeNonOperating | 12.36M | 15.41M | 1.73M | 10.10M |
| OperatingIncome | 177.68M | -274.21M | -249.46M | -412.26M |
| OperatingExpense | 251.67M | 203.60M | 132.88M | 277.06M |
| OtherOperatingExpenses | 30.00M | -2.44M | -30.81M | -636.69M |
| DepreciationAmortizationDepletionIncomeStatement | 7.81M | 13.82M | 11.36M | 8.98M |
| DepreciationAndAmortizationInIncomeStatement | 7.81M | 13.82M | 11.36M | 8.98M |
| ResearchAndDevelopment | 153.03M | 115.72M | 62.55M | 815.91M |
| SellingGeneralAndAdministration | 60.82M | 76.50M | 89.78M | 88.86M |
| SellingAndMarketingExpense | 4.45M | 3.91M | 2.82M | 287.00K |
| GeneralAndAdministrativeExpense | 56.38M | 72.58M | 86.97M | 88.57M |
| OtherGandA | 34.03M | 43.59M | 50.20M | 49.81M |
| SalariesAndWages | 22.35M | 29.00M | 36.77M | 38.76M |
| GrossProfit | 429.35M | -70.61M | -116.57M | -135.21M |
| CostOfRevenue | 105.83M | 124.37M | 183.99M | 238.19M |
| TotalRevenue | 535.18M | 53.76M | 67.42M | 102.99M |
| OperatingRevenue | 535.18M | 53.76M | 67.42M | 102.99M |
| Line Item | 2021-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 168.32K | |||
| OrdinarySharesNumber | 224.34M | 223.99M | 194.95M | 187.12M |
| ShareIssued | 224.34M | 223.99M | 194.95M | 187.29M |
| TotalDebt | 38.97M | 41.82M | 42.09M | 28.89M |
| TangibleBookValue | 671.45M | 488.60M | 501.48M | 675.24M |
| InvestedCapital | 696.61M | 516.94M | 533.25M | 688.48M |
| WorkingCapital | 454.07M | 291.99M | 427.80M | 582.28M |
| NetTangibleAssets | 671.45M | 488.60M | 501.48M | 675.24M |
| CapitalLeaseObligations | 38.97M | 41.82M | 42.09M | 28.89M |
| CommonStockEquity | 696.61M | 516.94M | 533.25M | 688.48M |
| TotalCapitalization | 696.61M | 516.94M | 533.25M | 688.48M |
| TotalEquityGrossMinorityInterest | 696.61M | 516.94M | 533.25M | 688.48M |
| StockholdersEquity | 696.61M | 516.94M | 533.25M | 688.48M |
| GainsLossesNotAffectingRetainedEarnings | 2.07B | 2.06B | 1.82B | 1.73B |
| OtherEquityAdjustments | 2.07B | 2.06B | 1.82B | 1.73B |
| ForeignCurrencyTranslationAdjustments | -67.00K | -139.00K | -34.00K | |
| TreasuryStock | 0.00 | 0.00 | 1.48M | 5.82M |
| RetainedEarnings | -1.40B | -1.57B | -1.31B | -1.06B |
| CapitalStock | 26.92M | 26.88M | 23.40M | 22.45M |
| CommonStock | 26.92M | 26.88M | 23.40M | 22.45M |
| TotalLiabilitiesNetMinorityInterest | 106.22M | 271.31M | 327.22M | 469.77M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 33.87M | 84.92M | 170.99M | 112.03M |
| OtherNonCurrentLiabilities | 19.00K | 264.00K | ||
| NonCurrentDeferredLiabilities | 227.00K | 48.10M | 72.55M | 86.34M |
| NonCurrentDeferredRevenue | 0.00 | 48.10M | 72.55M | 86.34M |
| NonCurrentDeferredTaxesLiabilities | 227.00K | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 33.64M | 36.82M | 37.11M | 25.42M |
| LongTermCapitalLeaseObligation | 33.64M | 36.82M | 37.11M | 25.42M |
| LongTermProvisions | 61.32M | |||
| CurrentLiabilities | 72.35M | 186.39M | 156.22M | 357.73M |
| OtherCurrentLiabilities | 18.42M | 40.17M | 34.98M | 42.13M |
| CurrentDeferredLiabilities | 0.00 | 44.58M | 36.78M | 58.92M |
| CurrentDeferredRevenue | 0.00 | 44.58M | 36.78M | 58.92M |
| CurrentDebtAndCapitalLeaseObligation | 5.32M | 5.00M | 4.98M | 3.47M |
| CurrentCapitalLeaseObligation | 5.32M | 5.00M | 4.98M | 3.47M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 11.13M | 10.54M | 7.78M | 7.21M |
| CurrentProvisions | 1.96M | 37.40M | 1.92M | 122.04M |
| PayablesAndAccruedExpenses | 35.53M | 48.69M | 69.78M | 123.96M |
| Payables | 35.53M | 48.69M | 69.78M | 123.96M |
| OtherPayable | 38.00K | |||
| TotalTaxPayable | 18.25M | 654.00K | 1.53M | 1.66M |
| IncomeTaxPayable | 18.25M | 654.00K | 610.00K | 739.00K |
| AccountsPayable | 17.27M | 48.03M | 68.25M | 122.26M |
| TotalAssets | 802.83M | 788.25M | 860.47M | 1.16B |
| TotalNonCurrentAssets | 276.41M | 309.87M | 276.44M | 218.22M |
| OtherNonCurrentAssets | 1.51M | 1.71M | 1.67M | 1.00K |
| NonCurrentPrepaidAssets | 1.36M | 1.22M | ||
| NonCurrentDeferredAssets | 5.09M | 1.19M | 1.30M | 2.86M |
| NonCurrentDeferredTaxesAssets | 5.09M | 1.19M | 1.30M | 2.86M |
| NonCurrentAccountsReceivable | 302.00K | 515.00K | ||
| GoodwillAndOtherIntangibleAssets | 25.15M | 28.34M | 31.78M | 13.24M |
| OtherIntangibleAssets | 12.69M | 15.88M | 19.32M | 13.24M |
| Goodwill | 12.46M | 12.46M | 12.46M | 0.00 |
| NetPPE | 244.65M | 278.62M | 241.70M | 200.39M |
| AccumulatedDepreciation | -78.53M | -37.42M | -29.57M | -47.02M |
| GrossPPE | 323.19M | 316.05M | 271.27M | 247.41M |
| Leases | 37.84M | 39.57M | 41.18M | 31.55M |
| ConstructionInProgress | 183.65M | 178.99M | 138.46M | 124.54M |
| OtherProperties | 1.60M | 1.95M | 2.30M | 440.00K |
| MachineryFurnitureEquipment | 71.91M | 68.00M | 62.86M | 63.61M |
| BuildingsAndImprovements | 28.20M | 27.54M | 26.47M | 27.27M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 526.41M | 478.38M | 584.03M | 940.02M |
| OtherCurrentAssets | 5.21M | 5.46M | 5.34M | 8.29M |
| AssetsHeldForSaleCurrent | 1.60M | 2.42M | 10.47M | 0.00 |
| PrepaidAssets | 792.00K | 1.07M | 4.51M | 5.72M |
| Inventory | 541.00K | 24.80M | 23.99M | 56.16M |
| FinishedGoods | 0.00 | |||
| RawMaterials | 541.00K | 24.80M | 23.99M | 56.16M |
| Receivables | 32.90M | 39.51M | 39.44M | 53.74M |
| OtherReceivables | 7.53M | 7.10M | 8.30M | |
| TaxesReceivable | 11.29M | 18.08M | 24.84M | 35.23M |
| AccountsReceivable | 14.08M | 14.33M | 6.29M | 18.50M |
| CashCashEquivalentsAndShortTermInvestments | 485.37M | 405.11M | 500.28M | 816.11M |
| OtherShortTermInvestments | 3.62M | 2.66M | 4.49M | 4.65M |
| CashAndCashEquivalents | 481.75M | 402.45M | 495.80M | 811.46M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 83.41M | -323.09M | -379.40M | -861.03M |
| RepurchaseOfCapitalStock | -30.91M | |||
| RepaymentOfDebt | -5.11M | -5.19M | -4.22M | -28.18M |
| IssuanceOfDebt | 0.00 | 0.00 | ||
| IssuanceOfCapitalStock | 0.00 | 235.84M | 66.48M | 404.06M |
| CapitalExpenditure | -18.44M | -55.20M | -93.22M | -127.90M |
| EndCashPosition | 481.75M | 402.45M | 495.80M | 811.46M |
| BeginningCashPosition | 402.45M | 495.80M | 811.46M | 1.32B |
| EffectOfExchangeRateChanges | 1.00M | -1.15M | 836.00K | 4.94M |
| ChangesInCash | 78.29M | -92.19M | -316.50M | -516.07M |
| FinancingCashFlow | -5.11M | 230.89M | 63.17M | 344.96M |
| CashFlowFromContinuingFinancingActivities | -5.11M | 230.89M | 63.17M | 344.96M |
| ProceedsFromStockOptionExercised | 0.00 | 246.00K | 910.00K | 3.19M |
| NetCommonStockIssuance | 0.00 | 235.84M | 66.48M | 373.15M |
| CommonStockPayments | -30.91M | |||
| CommonStockIssuance | 0.00 | 235.84M | 66.48M | 404.06M |
| NetIssuancePaymentsOfDebt | -5.11M | -5.19M | -4.22M | -28.18M |
| NetLongTermDebtIssuance | -5.11M | -5.19M | -4.22M | -28.18M |
| LongTermDebtPayments | -5.11M | -5.19M | -4.22M | -28.18M |
| LongTermDebtIssuance | 0.00 | 0.00 | ||
| InvestingCashFlow | -18.44M | -55.20M | -93.50M | -127.90M |
| CashFlowFromContinuingInvestingActivities | -18.44M | -55.20M | -93.50M | -127.90M |
| NetInvestmentPurchaseAndSale | 0.00 | 0.00 | ||
| SaleOfInvestment | 0.00 | |||
| PurchaseOfInvestment | 0.00 | 0.00 | ||
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | -277.00K | 0.00 |
| PurchaseOfBusiness | 0.00 | 0.00 | -277.00K | 0.00 |
| NetIntangiblesPurchaseAndSale | -4.13M | -2.88M | -5.20M | -3.68M |
| PurchaseOfIntangibles | -4.13M | -2.88M | -5.20M | -3.68M |
| NetPPEPurchaseAndSale | -14.31M | -52.32M | -88.02M | -124.22M |
| PurchaseOfPPE | -14.31M | -52.32M | -88.02M | -124.22M |
| OperatingCashFlow | 101.85M | -267.89M | -286.18M | -733.13M |
| CashFlowFromContinuingOperatingActivities | 101.85M | -267.89M | -286.18M | -733.13M |
| TaxesRefundPaid | -3.15M | -3.89M | -128.00K | -502.00K |
| InterestReceivedCFO | 11.07M | 15.85M | 1.79M | 81.00K |
| InterestPaidCFO | -2.33M | -2.38M | -4.61M | -9.79M |
| ChangeInWorkingCapital | -163.96M | -94.13M | -184.36M | -69.55M |
| ChangeInOtherWorkingCapital | -35.44M | -25.84M | -58.80M | -1.58M |
| ChangeInOtherCurrentLiabilities | 0.00 | 0.00 | -20.00K | |
| ChangeInOtherCurrentAssets | 1.34M | 0.00 | 0.00 | |
| ChangeInPayablesAndAccruedExpense | -140.58M | -30.10M | -96.18M | 179.32M |
| ChangeInPayable | -140.58M | -30.10M | -96.18M | 179.32M |
| ChangeInAccountPayable | -140.58M | -30.10M | -96.18M | 179.32M |
| ChangeInPrepaidAssets | 16.49M | 8.97M | -3.12M | |
| ChangeInInventory | 590.00K | -47.94M | -47.85M | -227.46M |
| ChangeInReceivables | 11.47M | 9.75M | 18.47M | -16.68M |
| ChangesInAccountReceivables | 11.47M | 9.75M | 18.47M | -16.68M |
| OtherNonCashItems | -13.20M | -14.24M | -302.00K | -480.74M |
| StockBasedCompensation | 4.12M | 7.70M | 9.19M | 14.96M |
| ProvisionandWriteOffofAssets | -25.84M | -58.80M | 0.00 | |
| AssetImpairmentCharge | 58.97M | 56.31M | 105.68M | 208.64M |
| DepreciationAmortizationDepletion | 18.81M | 23.39M | 23.74M | 15.67M |
| DepreciationAndAmortization | 18.81M | 23.39M | 23.74M | 15.67M |
| OperatingGainsLosses | 646.00K | 3.48M | 11.98M | 587.00K |
| GainLossOnSaleOfPPE | 3.48M | 11.98M | 587.00K | |
| NetIncomeFromContinuingOperations | 190.88M | -259.97M | -249.16M | -412.50M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for CVAC
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|